Kovina Therapeutics is a preclinical biotechnology company focused on developing innovative antiviral therapeutics aimed at treating cancers and premalignant infections associated with Human Papillomavirus (HPV). The company recognizes the significant global health burden posed by HPV, which is responsible for nearly all cervical cancers and a majority of oropharyngeal cancers. Current treatment options, such as surgery, radiation, and chemotherapy, often come with severe side effects, and existing HPV vaccines do not address the millions of individuals already infected. Kovina's unique approach involves proprietary drug-like compounds that specifically target and inactivate a crucial HPV protein consistently expressed in early and cancerous stages of infection, leading to the death of HPV-infected cells. This strategy aims to halt the progression of HPV infections and provide therapeutic options for those already diagnosed with HPV-related cancers.

Kovina Therapeutics is committed to offering novel treatment alternatives for patients suffering from HPV infections, emphasizing a non-surgical approach to managing these conditions. The company has received multiple grants from the National Institutes of Health (NIH) to support its research and development efforts, including funding to advance treatments for oropharyngeal cancers and premalignant infections caused by HPV. These grants reflect Kovina's potential to make significant contributions to the field of antiviral therapeutics and provide hope for patients facing the challenges of HPV-related diseases.

United States

Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral therapeutics designed to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV)

Kovina Therapeutics

Company Details